Corsini, Alberto

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 8,961

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 796

Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions

Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 578

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 370

Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease

Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005) · The Journal of Neuroscience

Genetic Neurodegenerative DiseasesCholesterol and Lipid Metabolism

Cited by 298

Glycosylation of Human Apolipoprotein E

Wernette-Hammond, M. E., Lauer, S. J., Corsini, A., Walker, D., Taylor, J. M., & Rall, S. C. (1989) · Journal of Biological Chemistry

Glycosylation and Glycoproteins ResearchViral Infectious Diseases and Gene Expression in Insects

Cited by 149

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

Poli, A., Barbagallo, C. M., Cicero, A. F. G., Corsini, A., Manzato, E., Trimarco, B., Bernini, F., Visioli, F., Bianchi, A., Canzone, G., et al. (2018) · Pharmacological Research

Lipoproteins and Cardiovascular HealthNatural Products and Biological Research

Cited by 134

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 132

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages

Adorni, M. P., Cipollari, E., Favari, E., Zanotti, I., Zimetti, F., Corsini, A., Ricci, C., Bernini, F., & Ferri, N. (2017) · Atherosclerosis

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 130

Statin drug interactions and related adverse reactions

Bellosta, S., & Corsini, A. (2012) · Expert Opinion on Drug Safety

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 111

The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk

Corsini, A. (2003) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 82

Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease

Zimetti, F., Caffarra, P., Ronda, N., Favari, E., Adorni, M. P., Zanotti, I., Bernini, F., Barocco, F., Spallazzi, M., Galimberti, D., et al. (2016) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 75

Lipid Lowering Drugs: Present Status and Future Developments

Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

Depression and cardiovascular risk-association among Beck depression inventory, PCSK9 levels and insulin resistance

Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiac Health and Mental Health

Cited by 51

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

Ruscica, M., Busnelli, M., Runfola, E., Corsini, A., & Sirtori, C. R. (2019) · International Journal of Molecular Sciences

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 33

Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy

Cesaro, A., Acerbo, V., Scialla, F., Zito, A., Porcelli, G., Panico, D., Argenziano, G., Iaria, D., Monaco, M. G., De Sio, V., et al. (2026) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 11

Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review

Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 10